LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.

Revenue
+9.88%
EPS
+27.4%
Free cash flow
−31.0%
Total debt
−31.2%

Quarter to September 2026, against a year earlier

90.21 0.93 −1.02%
Market cap
$5.0B
P/E
25.6×
Fwd P/E
19.8×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more quarters

360.92 362.26 390.59 393.10
Revenue Growth
12.15% 14.33% 10.80% 9.88%
Gross Profit
239.77 243.75 273.67 265.00
Operating Income
42.58 41.47 49.48 28.40
EBT
27.63 27.49 18.48 46.80
Income after Tax
30.92 23.15 108.68 34.40
Net Income Common
30.91 22.29 108.57 34.30
EPS (Diluted)
0.56 0.40 1.93 0.60
Shares (Diluted, Weighted)
54.55 55.94 56.27 57.40
Gross Margin
66.43% 67.29% 70.07% 67.41%
EBIT Margin
11.80% 11.45% 12.67% 7.22%
Net Profit Margin
8.56% 6.15% 27.80% 8.73%
EBITDA
63.08 61.84 72.62 —
EBIT
42.58 41.47 49.48 28.40

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026